v3.26.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Operating activities:    
Net income $ 849,070 $ 220,431
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization expense 142,593 105,702
Share-based compensation expenses 393,247 387,096
Acquired in-process research and development 20,518 691
Amortization of research and development cost share liability (64,345) (74,844)
Impairment of equity investments 0 34,216
Non-cash interest expense 7,937 0
Other items, net 12,465 9,595
Changes in operating assets and liabilities:    
Accounts receivable (227,823) (167,294)
Inventories (185,379) (22,662)
Other assets (6,746) 55,247
Accounts payable 20,759 (7,381)
Accrued expenses and other payables 201,527 165,886
Other liabilities 9,040 3,550
Net cash provided by operating activities 1,172,863 710,233
Investing activities:    
Purchases of property, plant and equipment (103,440) (148,317)
Purchase of intangible assets 0 (20,000)
Proceeds from sale or maturity of investments 5,872 1,800
Purchase of in-process research and development (20,518) (60,691)
Other investing activities (12,537) (10,612)
Net cash used in investing activities (130,623) (237,820)
Financing activities:    
Proceeds from the sale of future royalties 0 885,000
Repayment of long-term loan (32,535) (21,062)
Proceeds from short-term loans 58,204 221,521
Repayment of short-term loans 0 (275,782)
Repayment of sale of future royalties liability (2,556) 0
Payments of withholding taxes from share-based awards 0 (24,195)
Proceeds from option exercises and employee share purchase plan 145,005 177,038
Other financing activities (3,346) 0
Net cash provided by financing activities 164,772 962,520
Effect of foreign exchange rate changes, net 49,655 36,862
Net increase in cash, cash equivalents, and restricted cash 1,256,667 1,471,795
Cash, cash equivalents, and restricted cash at beginning of period 4,609,647 2,638,747
Cash, cash equivalents, and restricted cash at end of period 5,866,314 4,110,542
Supplemental cash flow information:    
Cash and cash equivalents 5,781,128 4,036,868
Short-term restricted cash 63,400 52,987
Long-term restricted cash 21,786 20,687
Income taxes paid 156,957 79,962
Interest expense paid 91,965 36,148
Supplemental non-cash information:    
Capital expenditures included in accounts payable and accrued expenses 49,079 52,057
ROU assets obtained in exchange for new operating lease liabilities $ 23,947 $ 19,127